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To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious
mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which
fail to measure the single crucial criteria of a successful intervention, namely impact on case incidence within a vertebrate popu-
lation (reduction in reproductive number/effect size). Consequently, any reduction in new infections due to drug treatment (and
how this may be influenced by differing transmission settings) is not currently examined, limiting the translation of any find-
ings. We describe the use of a laboratory populationmodel to assess how individual antimalarial drugs can impact the number
of secondary Plasmodium berghei infections over a cycle of transmission. We examine the impact of multiple clinical and pre-
clinical drugs on both insect and vertebrate populations at multiple transmission settings. Both primaquine (>6 mg/kg of body
weight) and NITD609 (8.1 mg/kg) have significant impacts across multiple transmission settings, but artemether and lumefan-
trine (57 and 11.8 mg/kg), OZ439 (6.5 mg/kg), and primaquine (<1.25 mg/kg) demonstrated potent efficacy only at lower-trans-
mission settings. While directly demonstrating the impact of antimalarial drug treatment on vertebrate populations, we addi-
tionally calculate effect size for each treatment, allowing for head-to-head comparison of the potential impact of individual
drugs within epidemiologically relevant settings, supporting their usage within elimination campaigns.
Malaria is a devastating global human disease caused by pro-tozoan parasites of the genus Plasmodium, which is exclu-
sively transmitted by anopheline mosquitoes. Interventions in-
cluding long-lasting insecticidal nets and improved access to care
have substantially reduced globalmalariamorbidity andmortality
over the last decade (1). In sub-Saharan Africa, approximately
40%of the population residing in areas with stable transmission is
now estimated to experience an entomological inoculation rate
(EIR) of less than one infectious bite per year (2). Despite these
successes, the human burden remains high, with an estimated 219
million cases globally in 2013 (1). However, the tools currently
available are insufficient to interrupt transmission in areas of high
endemicity (3), and there remains growing concern over the
spread of insecticide and parasite drug resistance (4). To achieve
elimination, and ultimately eradication, there is therefore a need
to develop novel tools that target the parasite at the weakest points
in its life cycle. One option to achieve this is to target Plasmodium
using either transmission-blocking drugs (TBDs) or transmis-
sion-blocking vaccines (TBVs) which could, either alone or in
combination with other interventions, interrupt transmission or
achieve local elimination of the parasite (5).
In recent years, a large number of potential new antimalarial
TBDs have been discovered. Those that are comparatively ad-
vanced in the development pipeline include the synthetic en-
doperoxidase OZ439, which has proven activity against the asex-
ual stages of the parasite (6) and is currently in phase IIa clinical
trials, and the spiroindolone NITD609, which has previously
demonstrated potent dose-responsive activity against the sexual
stages of Plasmodium falciparum (7). These relatively new drugs
add to the battery of more comprehensively analyzed TBDs, such
as the clinically used antimalarial drug combination artemether-
lumefantrine (A-L) and the 8-aminoquinoline primaquine. A-L is
a widely used artemisinin combination therapy (ACT) approved
for the treatment of uncomplicated P. falciparum malaria. Al-
though it has been speculated previously that artemether is re-
sponsible primarily for the transmission-blocking activity of this
ACT, lumefantrine has also been shown to inhibitmosquito trans-
mission (7–9). Primaquine exhibits poor activity against asexual
parasites but has established activity against mature gametocytes
(8, 9) and is the only widely available drug capable of clearing
mature P. falciparum gametocytes and hence preventing onward
transmission (10, 11). The World Health Organization (WHO)
has recently recommended the use of a single dose of 0.25 mg of
primaquine/kg of body weight in addition to ACTs in malaria
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eliminationprograms (1). The use of primaquine in thismanner is
predicted to slow the emergence of artemisinin resistance while
reducing toxicity concerns related to hemolysis inG6PD-deficient
individuals. The effect of primaquine on reducing onward trans-
mission remains unproven (12).
Given the current resurgent interest in interrupting malaria
transmission (5, 13), a wide range of novel potential TBDs are
currently undergoing assessment and subsequent triage in a num-
ber of transmission-blocking assays. Examples of these assays in-
clude multiple early/late stage gametocyte assays (14–20), exflag-
ellation/male gamete assays (9, 21, 22), ookinete conversion assays
(23–25), and sporozoite formation assays (26–28). Although typ-
ically cheap and of high to medium throughput, these assays have
diverse and divergent outputs and usually yield data of low bio-
logical content. The current “gold standard” assay to assess trans-
mission-blocking interventions, the standard membrane feeding
assay (SMFA), is also heavily utilized in the current TBD develop-
ment pipeline, typically assessing efficacy as a reduction in oocyst
prevalence and intensity within themosquitomidgut.While all of
these assays are undoubtedly valuable tools to identify and mea-
sure the potency of potential TBDs, none of them measure the
desired endpoint of a TBD, namely, the reduction in the number
of newmalaria infections in the target vertebrate population (13).
Instead, current methods measure convenient outputs, e.g., re-
duction in viable gametocytes (stage II to stage V) or reduction of
parasite burden (oocyst or sporozoite stages) within the mos-
quito. It is unclear how reductions in these surrogate endpoints
impact on subsequent mosquito-to-vertebrate transmission and,
consequently, the number of newmalaria infections or the repro-
ductive number (Ro). This strongly limits the potential translation
of their impact, but assessments of impact on human populations
are currently ethically challenging. Furthermore, future regula-
tory approval for TBDs is likely to require provision of data di-
rectly demonstrating their impact in vertebrate populations. To
address these issues, we developed a reliable and cost-effective
transmission-based mouse-to-mouse population model to assess
how individual (or combinations of) TBDs impact the number of
secondary cases of malaria over cycles of transmission within a
controlled laboratory setting (28). Themodel simulates a range of
different transmission intensities by varying the number of mos-
quito bites on each naive mouse (referred to as the mosquito bit-
ing rate [MBR]). The use of multiple MBRs allows us to estimate
the effect size of the intervention, which is a measure of the ability
of the treatment to reduce Ro (29). By calculating this important
parameter for individual TBDs, we aim to link “traditional” lab-
derived transmission-blocking assays to the potential practical
impact at the population level.
Here, we report the evaluation of a number of clinical and
preclinical TBDs in this population model over an entire trans-
mission cycle. We demonstrate the impact of individual TBDs on
bothmosquitoes and subsequentmice and estimate the effect sizes
for each drug regime, allowing, for the first time (to our knowl-
edge), head-to-head comparison of the potential impact of indi-
vidual TBDs on subsequent malarial infections and disease inci-
dence within vertebrate populations.
MATERIALS AND METHODS
Drug treatments.Artemether-lumefantrine (A-L; Coartem),OZ439, and
NITD609were tested in duplicate at a concentration equivalent to 3 times
the 90% effective dose (ED90; reduction of asexual parasitemia by 90% in
vivo). Primaquinewas tested at 4 different concentrations (12, 6, 1.25, and
0.25 mg/kg). The triple combination of A-L and primaquine was tested
using 2 different primaquine concentrations (12 and 0.25 mg/kg). All
treatments consisted of a single dose of drug. Each experiment included
three control treatments. The diluting agent for all test drugs, 1% methyl
cellulose (Sigma-Aldrich no. M7140), was used as a negative control (re-
ferred to as “no-drug control”). Sulfadiazine (Sigma-Aldrich no. S6387)
and atovaquone (ATV; Sigma-Aldrich no. A7968) were used as negative
and positive drug controls, respectively (28, 30). The inability of sulfadi-
azine to reduce gametocytemia under the conditions tested is demon-
strated in Fig. S2 in the supplemental material. All treatments were
delivered by oral gavage except sulfadiazine and ATV, which were admin-
istered by intraperitoneal (i.p.) injection. Table 1 summarizes the treat-
ments and doses used.
Mouse-to-mouse transmission model. For each treatment regime,
mouse-to-mouse transmission was performed in duplicate (except prim-
aquine, where individual doses were tested in single experiments) tomax-
imize statistical significance in balance with cost, with general parasite
maintenance carried out as previously described (28). A schematic of the
model is shown in Fig. 1. Briefly, for each treatment group, five female TO
mice (6 to 8 weeks old) were infected with Plasmodium berghei clone
507cl1 (31) by syringe inoculation (i.p.). All care and handling of animals
was in accordance with the Guidelines for Animal Care and Use prepared
by Imperial College London. At day 9 postinfection, tail blood drops were
examined for the presence of exflagellation, and mice were given the ap-
propriate drug/control treatment by the appropriate route (see Table 1).
Blood stage infections were monitored on Giemsa-stained tail blood
smears, before and 24 h after treatment, as previously described (28).
Ten days postinfection and 24 h posttreatment, the mice were anes-
thetized and exposed to 500 starved female Anopheles stephensi (line sd
500) mosquitoes. Mosquitoes that did not take a blood meal were dis-
TABLE 1 Drug treatments used in the mouse-to-mouse modela
Drug(s) Dose(s) Diluting agent Volume(s) (l) Delivery method
No drug (control) 1% methyl cellulose Water 100–200 Oral
SD (control) 8.4 mg/kg Water 100 i.p.
ATV (control) 0.3 mg/kg DMSO 100 i.p.
A-L 57 and 11.8 mg/kg for A and L, respectively 1%MC 50 each Oral
PQ 12, 6, 1.25, or 0.25 mg/kg 1%MC 100 Oral
A-L and PQ 57 and 11.8 mg/kg for A and L, respectively, and
12 or 0.25 mg/kg PQ
1%MC 50 for A and L and 100 for PQ Oral
OZ439 6.5 mg/kg 1%MC 100 Oral
NITD609 8.1 mg/kg 1%MC 100 Oral
a Drugs were prepared in either water, dimethyl sulfoxide (DMSO), or 1% methyl cellulose (MC), as stated. Either 100 or 200 l of 1% MC was used for the no-drug control,
depending on the maximum drug volume for that experiment. Treatments were delivered by oral gavage or i.p. injection as indicated, 24 h prior to mosquito feeding. ATV,
atovaquone; PQ, primaquine; A-L, artemether and lumefantrine; SD, sulfadiazine.
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carded, and the remaining mosquitoes were maintained on 8% (wt/vol)
fructose and 0.05% (wt/vol) p-aminobenzoic acid at 19°C and 80% rela-
tive humidity. On day 10 postfeeding, midguts were dissected from a
random sample of 50 mosquitoes per cage and oocyst prevalence (per-
centage of infected mosquitoes) and intensity (mean number of parasites
per midgut) were recorded. For each treatment group, oocyst prevalence
andmeanoocyst intensitywere compared to the no-drug control group to
calculate “classical” inhibition of transmission. All mosquito dissections
to assess oocyst intensity and prevalence were performed under random-
ized and double-blind conditions.
The remaining mosquitoes were maintained until 21 days postinfec-
tion, when salivary gland sporozoites were at their peak of infectiousness
(28). Individual anesthetized naive mice were exposed for 20 min to pre-
determined numbers of potentially infectious mosquitoes, randomly se-
lected from the appropriate mosquito population. For each treatment
group, five individual naive mice were exposed to either 2, 5, or 10 mos-
quito bites. This range of MBRs (simulating different transmission inten-
sities) is necessary to calculate effect size (see below). Successful feeding
was confirmed by the presence of blood in themosquito abdomen.Where
necessary, additional mosquitoes were given the opportunity to feed until
the required number of successful bites was achieved. Postfeeding, all
mosquitoes were individually dissected to determine the prevalence of
salivary gland sporozoites. Glandswere directly dissected onto a glass slide
and covered with a coverslip, and intensities were scored on a log scale
(score of 0 no sporozoites visible; 1 1 to 10 sporozoites visible; 2 10
to 100 sporozoites visible; 3  100 to 1,000 sporozoites visible; 4 
1,000 sporozoites visible). For each treatment group, sporozoite preva-
lence and mean sporozoite intensity were compared to the no-drug con-
trol group to calculate inhibition. The “bitten” mice were allowed to re-
cover and maintained for 10 days postfeeding. Daily tail blood smears
were performed from days 4 to 10 to establish prepatency, parasitemia,
and gametocytemia.
Data reporting proportion of biting mosquitoes with salivary gland
sporozoites, oocyst intensity, and oocyst prevalence from all experiments
are included in Dataset S1 in the supplemental material.
Statistical analysis. Generalized linear mixed models were used to
estimate the overall effectiveness of the different interventions combining
data fromall repeat replicates (32). Efficacy of the treatment (compared to
the no-drug control) was included as a fixed effect, while the mouse-to-
mosquito transmission parameters were included as random effects. For
the oocyst and sporozoite prevalence data, we assumed a binomial error
structure, while for oocyst, asexual parasite, and gametocyte intensity, we
used a zero-inflated negative binomial distribution. The impact on sporo-
zoite intensity was assessed by looking at differences in sporozoite score,
which was assumed to follow a Poisson distribution. Ninety-five percent
confidence intervals were estimated by bootstrapping, and the model was
selected using a likelihood ratio test.
The overall effectiveness of an intervention over one round of trans-
mission (from mouse to mosquito to mouse) can be quantified by esti-
mating its ability to reduce the basic reproduction number. This has been
termed the effect size (29). If it is assumed that that all infectious mosqui-
toes are equally infectious, this can be estimated by fitting a chain bino-
mial model (33). A full description of the methodology is given in refer-
ence 28. The models were fitted to the data using maximum likelihood
methods and the 95% confidence interval estimates obtained from the
likelihood profile.
Ethical statement. All procedures were performed in accordance
with the terms of the United Kingdom Animals (Scientific Procedures)
Act (PPL 70/7185) and were approved by the Imperial College Ethical
Review Committee. The Office of Laboratory Animal Welfare (OLAW)
Assurance for Imperial College covers all Public Health Service (PHS)-
supported activities involving live vertebrates in the United States
(A5634-01).
RESULTS
Mouse-to-mousemodel and drug treatments.Antimalarials and
clinical TBD candidates (Table 1) were screened formalaria trans-
mission-blocking efficacy using the mouse-to-mouse model (Fig.
1). Further details regarding treatment and controls are described
inMaterials andMethods. All raw data generated from individual
experiments are given in Dataset S1 in the supplemental material.
Effect on parasite transmission to, and within, themosquito
vector. The impact of drugs administered to groups of P. berghei-
infected mice on the development of oocysts in the midgut and
sporozoites in the salivary glands of Anopheles stephensi mosqui-
toes was recorded. The percentages of inhibition of oocyst and
sporozoite intensity and prevalence for each treatment regime
compared to those of the no-drug control were calculated (Fig. 2).
For the no-drug control, overall oocyst intensity was 47.7 (stan-
dard error of the mean [SEM]  4.0) and oocyst prevalence was
77.7%.
Compared to the no-drug control, A-L at 57mg/kg-11.8mg/kg
significantly reduced parasite intensity and prevalence in themos-
quito. Oocyst intensity was inhibited by 94% (95% confidence
interval [CI] of 88 to 97), oocyst prevalence by 41% (95%CI of 22
to 58), and ensuing sporozoite intensity and prevalence by 68%
(95% CI of 56 to 77) and 61% (95% CI of 42 to 74), respectively.
Overall oocyst intensity for A-L was 6.78 (SEM 3.2), and oocyst
FIG 1 Themouse-to-mousemodel. A schematic illustrating the experimental
design of the mouse-to-mouse model using P. berghei and A. stephensi. For
each treatment group, the drug was administered to five P. berghei-infected
mice which were used to feed a cage of 500 female A. stephensi mosquitoes 24
h later. After 10 days, oocyst intensity and prevalence were determined. When
sporozoites were maximally infectious (21 days after feeding [28]), individual
naive mice were bitten by either 2, 5, or 10 mosquitoes (the mosquito biting
rate [MBR]). Salivary glands were dissected postbite to determine sporozoite
intensity and prevalence. The presence of infection in the peripheral blood of
challenged naive mice (i.e., the number of secondary malarial infections) was
monitored daily for 10 days postbite, with parasitemia, gametocytemia, and
time to patency recorded.
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prevalence was 69.5%.The impact of primaquine was clearly dose
dependent. At 12 mg/kg (independently or in combination with
A-L) and 6 mg/kg, oocyst and sporozoite development was com-
pletely blocked, whereas the drug had no significant effect at 1.25
and 0.25mg/kg (1.25mg/kg, oocyst intensity 39.1 [SEM 6.1]
and oocyst prevalence  80.6%; 0.25 mg/kg, oocyst intensity 
42.9 [SEM 6.1] and oocyst prevalence 79.1%). In this model,
the triple combination, containing primaquine (0.25 mg/kg), was
marginally but significantly (P 0.0014) less efficacious than A-L
alone (inhibition in oocyst intensity of 71% [95% CI of 43 to 86]
compared to 94% [95% CI of 88 to 97], mean oocyst intensity
16.6 [SEM  3.2], oocyst prevalence  69.5%). OZ439 signifi-
cantly inhibited both oocyst and sporozoite intensity and preva-
lence, though the efficacy was relatively modest (46% against
oocyst intensity [95% CI of 13 to 67], 29% against oocyst preva-
lence [95% CI of 13 to 46], mean oocyst intensity 26.6 [SEM
4.1], oocyst prevalence  56.3%). NITD609 significantly inhib-
ited both oocyst and sporozoite intensity andprevalence by85%
(mean oocyst intensity 0.1 [SEM 0.03], oocyst prevalence
8.3%). The atovaquone (ATV) positive control completely
blocked themosquito stages of infection, whereas the sulfadiazine
negative control, compared to the no-drug control, had no detect-
able effect on vertebrate-mosquito transmission.
Effect on transmission to secondary vertebrate populations
at differentmosquito biting rates.The impact of individual drug
regimens on malarial transmission from infected mosquitoes to a
secondary population of naive mice at different transmission in-
tensities (MBRs of 2, 5, and 10 bites) was assessed (the use of
differing MBRs permits the estimation of the key output, namely,
effect size). Table 2 presents the impact of each compound on
mouse infection, compared to that of the drug-free controls, illus-
trating the prepatent period between sporozoite inoculation and
observation of asexual parasites and the percentage reduction in
parasitemia and gametocytemia at day 10 postbite. The number of
secondary infections (infection prevalence of blood stage infec-
FIG 2 Transmission-blocking effect of drug treatments within the mosquito vector. Inhibition of oocyst intensity and prevalence (dark- and light-blue bars,
respectively) and sporozoite intensity and prevalence (dark- and light-red bars, respectively) in the mosquito vector after feeding on drug-treated infected mice.
Vertical lines denote 95% confidence interval estimates. Inhibition was calculated relative to the no-drug control. Red asterisks indicate statistically significant
(P 0.05) levels of inhibition.
TABLE 2 Effect of drug treatments on transmission to secondary mouse populationsa
Drug(s) (dose) Prepatent period in days (SEM)
% inhibition
Infection prevalence Parasitemia day 10 Gametocytemia day 10
No drug 5.7 (0.31) NA NA NA
A-L (57 and 11.8 mg/kg) 6.9 (0.65) 57.9b 50.4b 25.8
PQ (12 mg/kg) Not infected 100.0b 100.0b 100.0b
PQ (6 mg/kg) Not infected 100.0b 100.0b 100.0b
PQ (1.25 mg/kg) 5.4 (0.13) 0.0 4.4 37.4
PQ (0.25 mg/kg) 5.9 (0.19) 9.1 34.2b 7.7
A-L and PQ (12 mg/kg) Not infected 100.0b 100.0b 100.0b
A-L and PQ (0.25 mg/kg) 6.3 (0.53) 27.3 34.5 54.0
OZ439 (6.5 mg/kg) 6.1 (0.45) 12.0 13.1 12.4
NITD609 (8.1 mg/kg) Not infected 100.0b 100.0b 100.0b
a The prepatent period reduction in infection prevalence and reduction in asexual and sexual infection intensity (in infected mice) are illustrated. Percentage of inhibition was
calculated relative to the no-drug control. NA, not applicable. Results from all biting rates are included.
b Statistical significance (calculated using Fisher’s exact test for percent inhibition in infection prevalence and using bootstrapping, 10,000 replicates, for percent inhibition in
parasitemia and gametocytemia at day 10).
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tion) was assessed as the prevalence of blood stage infection in
mice 10 days after mosquito bites.
Artemether-lumefantrine significantly reduced the number of
secondary infections (58% reduction) compared to that of the
no-drug control (Table 2). Mice that did become infected exhib-
ited a longer prepatent period (6.9 0.65 versus 5.7 0.31 days)
and a significantly lower parasitemia at day 10 (50%, 95%CI of 39
to 60) than mice infected in the control arm. Primaquine given at
12 and 6 mg/kg completely blocked transmission to a secondary
mouse population but did not exhibit a potent effect at doses of
1.25 and 0.25 mg/kg. Primaquine given at a dose of 0.25 mg/kg
significantly inhibited parasitemia in infected mice by 34% (95%
CI of 11 to 51%) despite the lack of a detectable impact when
observing oocyst intensity/prevalence in the mosquito popula-
tion. Conversely, the triple combination of A-L and primaquine at
doses of 12 or 0.25 mg/kg resulted in complete transmission
blockade or no impact, respectively, consistent with themeasured
impact on oocyst and sporozoite numbers. Under the transmis-
sion settings examined and at the dose administered, OZ439 had
no significant impact on the number of secondary infections, par-
asitemia or gametocytemia, despite the significant inhibition ob-
served in both oocyst and sporozoite intensity and prevalence.
NITD609 resulted in 100% transmission blockade to secondary
populations, despite a low number of oocysts and sporozoites be-
ing observed in the mosquito population after treatment (Fig. 2).
As previously noted (28), increasing the MBR, not unexpectedly,
increased the proportion of mice infected (see Dataset S1 in the
supplemental material).
Effect size ofTBD treatment.The estimated effect size for each
drug is shown in Table 3. The drugs can be broadly divided into
three categories: thosewith total (100%),moderate (25% to 60%),
and low (10%) estimated effect sizes. As with the ATV positive
control, we estimated a 100% effect size for NITD609 (despite a
low number of oocysts and sporozoites being observed in mos-
quito populations [Fig. 2]) and for primaquine at 12 and 6mg/kg,
indicating that at the maximum exposure considered (MBR 
10), these drugs would result in elimination from these laboratory
populations. Drugs with amoderate estimated effect size included
A-L, OZ439, and primaquine at 1.25mg/kg (58%, 57%, and 29%,
respectively, at the stated doses), while the estimated effect size for
primaquine (alone) at 0.25 mg/kg was comparatively low (8%).
DISCUSSION
Using a mouse-to-mosquito-to-mouse population transmission
model, we have analyzed five clinical and preclinical antimalarial
drug candidates for transmission-blocking activity, individually
assessing impact upon both mosquito (oocyst and sporozoite)
and vertebrate (asexual and sexual blood stage) phases of devel-
opment. This allows for the head-to-head comparison of efficacy
and the estimation of effect size, thereby measuring the potential
ability of TBDs to reduce Ro. In this manner, we can simply triage
individual drugs by their potential impact on vertebrate popula-
tions. The TBDs examined can be broadly divided into three cat-
egories: those with total (100%), moderate (25% to 60%), or low
(10%) estimated effect sizes.
A 100% effect size was estimated when examining the ability of
the novel antimalarial drug candidate NITD609 to block malarial
transmission. As an inhibitor of Plasmodium protein synthesis,
NITD609 is known to act against multiple parasite life stages (7,
34) and has previously demonstrated excellent potency against P.
falciparum andP. berghei. In previous studies, examining the asex-
ual form of the parasite, a single oral dose of NITD609 at 100
mg/kg was reported to completely cure P. berghei-infected mice,
whereas 30mg/kg cured 50%ofmice and 10mg/kg could not clear
infection (34). In terms of activity as a TBD, it has previously been
shown to inhibit both early and late gametocyte development in a
dose-dependent manner between 5 and 500 nM (7). NITD609
demonstrates efficacy in an in vitro P. berghei ookinete conversion
assay, with a 50% inhibitory concentration (IC50) of 3 M, and
strongly inhibits transmission to mosquitoes in the SMFA (7).
Here, NITD609 showed excellent potential as a TBD. At a dose of
8.1 mg/kg, NITD609 exhibited a potent (but not total) ability to
inhibit transmission from mouse to mosquito and completely
blocked progression of the life cycle to subsequent mice with a
single dose. As NITD609 belongs to a novel, synthetic class of
antimalarials, the spiroindolones, if approved, it has strong pros-
pects for future usewhen targeting artemisinin-resistant parasites.
It is the first antimalarial with a novel mode of action to enter
phase IIa trials in the last 20 years. Our results, combined with
impressive data reported previously, clearly demonstrate that
NITD609 has exciting potential to be used as a potent single-dose
TBD in the near future. A 100% effect size was also observed when
examining the transmission-blocking efficacy of the control drug
ATV, supporting previous studies showing potency (28). ATV is
commonly administered with proguanil (Malarone) for treat-
ment and prevention of malaria; however, resistance against the
cytochrome bc1 complex that ATV targets is considered to be
widespread and comparatively easily generated (35).
Primaquine, a widely utilized antimalarial, additionally gener-
ated a 100% estimated effect size at higher dosages (12 and 6 mg/
kg). Its potent impact is strongly dose dependent; any induced
transmission-blocking effect in bothmosquito (Fig. 2) andmouse
(Table 2) populations is clearly reduced at the lower concentra-
tions examined (1.25 and 0.25 mg/kg), with moderate or low ef-
fect sizes generated correspondingly (29% or 8%, respectively). In
previous studies, primaquine has been reported to reduce game-
tocyte carriage in combination with an ACT, with a wide range of
studies reporting a significant reduction compared to that of the
ACT alone (10, 36–41). The infectiousness of treated gametocytes
to mosquitoes, or onward transmission and impact on new verte-
brate infections, was not examined within any of these studies.
TABLE 3 Effect size of individual drug treatmentsa
Effect size Drug(s) (dose) Effect size (95% CI)
Total ATV (0.3 mg/kg) 100 (96–100)
PQ (6 mg/kg) 100 (96–100)
NITD609 (8.1 mg/kg) 100 (96–100)
PQ (12 mg/kg) 100 (58–100)
A-L and PQ (12 mg/kg) 100 (58–100)
Moderate A-L (57 and 11.8 mg/kg) 58 (19–86)
OZ439 (6.5 mg/kg) 57 (31–75)
A-L and PQ (0.25 mg/kg) 42 (20–99)
PQ (1.25 mg/kg) 29 (29–69)
Low PQ (0.25 mg/kg) 8 (18–48)
SD (8.4 mg/kg) 0.1 (0.8–0.3)
a Drug treatments have been ranked in order of effect size and transmission-blocking
efficacy. Treatments have been broadly divided into three groups: drugs with total
(100%) effect size, drugs with a moderate effect size, and drugs with a low effect size.
ATV, atovaquone; PQ, primaquine; A-L, artemether-lumefantrine; SD, sulfadiazine.
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Two older studies have directly examined the ability of prima-
quine to directly inhibit transmission in a small number of pa-
tients (n 2) (42, 43). In these studies, a single dose of 45 mg of
primaquine base proved to inhibit onward transmission from hu-
man to human (1 from a group of 4 individuals developed patent
P. falciparum infection posttreatment at a single MBR of 75). De-
spite this raft of largely positive findings, the transmission-block-
ing efficacy of primaquine, particularly at lower doses and in com-
bination with an ACT, remains poorly understood (1, 12, 44, 45).
Our results corroborate previously observed dose dependency,
although the doses at which we identified a significant effect were
considerably higher. We observe no additional benefit of adding
primaquine (at 0.25 mg/kg) to the A-L combination, consistent
with two recent Cochrane reviews which concluded that there was
no clear evidence as to whether primaquine (in combination with
an ACT) can directly reduce onward transmission in an area
where malaria is endemic, even if it significantly reduces gameto-
cyte prevalence (44, 45). In light of these, and our, findings, the
role of primaquine as a TBD inmalaria treatment should continue
to be examined carefully in subsequent studies, especially at low
dosages. Several valuable clinical trials to determine the most ef-
fective dosing are under way (10).
A moderate effect size was observed when examining two fur-
ther antimalarials, A-L and OZ439. A-L is a common ACT cur-
rently approved for treatment of uncomplicated P. falciparum
malaria. Our data demonstrated only a moderate transmission-
blocking effect of A-L at the tested dosages on P. berghei transmis-
sion to mosquitoes, which translated into a significant reduction
in secondary malaria infections in mice. This is consistent with
previous studies of P. falciparum in humans given this ACT as
first-line therapy, which have demonstrated reduction in both ga-
metocyte carriage posttreatment and onward transmission to
mosquitoes following A-L treatment (11, 36, 46–50). The data
described here further demonstrate the potential impact of A-L to
achieve a substantial reduction in malaria infection within verte-
brate populations at the dosages tested. Previous studies have dis-
cussed the translation of laboratory-based transmission of Plas-
modium compared to transmission in the field (28, 51, 52).
Translation of an effect size into impact in epidemiological set-
tings requires further consideration of the mode of delivery, cov-
erage, and the balance between reducing onward transmission
and protection from reinfection (53). Nevertheless, an estimated
effect size of 58% suggests that use of such drugs could lead to
significant reductions in transmission if deployed appropriately in
low-transmission settings.
Our results confirm that the endoperoxide, OZ439, has poten-
tial as a transmission-reducing drug. OZ439 has several advan-
tages over artemisinin derivatives, including prolonged plasma
exposure, higher potency, and its stable, synthetic nature (6). It
has shown comparable efficacy in the treatment of P. falciparum
and Plasmodium vivax patients (6), is undergoing phase IIa clini-
cal trials, and is intended for use as a single-dose combination
therapy for acute malaria. It has previously been demonstrated to
completely cure P. berghei-infected mice (blood stage infection)
with a single oral dose of 20 mg/kg (6) but has no effect on P.
berghei ookinete development in in vitro assays at 10M, suggest-
ing it functions prior to the ookinete stage (20). It has additionally
demonstrated a potent effect in the SMFAwith P. falciparum at 10
M (20). Here, when administered 24 h prefeed at the tested dose
of 6.5 mg/kg, OZ439 significantly reduced oocyst and sporozoite
development in the mosquito but did not significantly reduce the
number of secondary mouse infections. Despite this, when mos-
quito and mouse data were collated and examined using a chain-
binomialmodel, amoderate effect size was estimated, comparable
to that observed when using A-L at 3 ED90. Recent studies using
SCIDmice have suggested promising results against asexual blood
stage infection using a dose of 19.5 mg/kg. Future studies should
aim to complement these results by assessing the transmission-
blocking efficacy of OZ439 at this higher dose. Additionally, eval-
uation of potential partner drugs forOZ439 is under way, with the
aim of increasing the transmission-blocking potency of treatment
and thus combating potential emerging resistance to the com-
pound in the future.
The use of the mouse-to-mouse model addresses key gaps in
our existing knowledge (54) that other transmission-blocking as-
says cannot, being the only fully in vivo model that measures the
impact of an intervention on mosquito-to-vertebrate and verte-
brate-to-vertebrate transmission. The resulting generation of ef-
fect size can be subsequently used within mathematical models of
malaria transmission to predict the public health significance of
individual TBDs in different settings and in combination with
different interventions. These studies will, as data accumulate, also
allowus to correlate “standard” transmission-blocking assay outputs
(e.g., reduction in oocyst intensity/prevalence) to reduction in para-
site prevalence/intensity in subsequent vertebrate populations. The
use of the tractable rodentmalaria parasiteP. berghei provides a safe,
cost-effective, and robust population model to examine these pa-
rameters. We are fully aware that any findings using rodent para-
sites require validation with respect to human malaria parasites;
however, early-stage efficacy trials of this type using human vol-
unteers are currently technically and ethically impossible (13).We
are additionally aware that differences in drug pharmacokinetics
(PK) between mice and humans are critical to any field extrapo-
lation of the data (55, 56). Recognizing that the rate of drug clear-
ance in rodents is approximately three times faster than that in
humans (55–57), drugs given to rodents at 3 ED90, in compari-
son with an equivalent allometric dose in humans, will potentially
result in lower levels of active circulating TBD 24 h posttreatment,
potentially underpredicting the impact of compounds. To en-
hance our understanding of the biological process of metabolism
and clearance of specific drugs, it would be advantageous for fu-
ture studies to compare PK data for individual TBDs in rodents
and humans at multiple time points posttreatment.
The systematic development, examination, approval, and wide-
spread use of new antimalarial TBDs will require phase 3 trials, with
successful outcome determined as the reduction in transmission
measured by decreased incidence ofmalarial infection. Given the ex-
ceptionallyhighcosts of such studies, and the subsequent ethical con-
siderations, it is both important and logical to set realistic go/no-go
criteria for efficacy before such trials. It is additionally highly advan-
tageous to triage potentially effective drugs byhead-to-head compar-
ison prior to development to this level. The studies described here
assist this comparison in a cost-effective, ethical, safe, and robust
manner. Our results demonstrate that different TBDs have various
transmission-blocking potencies at both the mosquito, vertebrate,
andpopulation levels, andhence successful formulation for theirfield
utilization will differ in various transmission settings. The intelligent
use of specific antimalarial drugswill require careful consideration of
TBD efficacy, effect size, and transmission intensity/EIR in targeted
areas. Even drugs with high transmission-blocking levels are likely to
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have the greatest impact if delivered as part of focal case detection
strategies in low-transmission settings in which a high proportion of
the infectious reservoir is treated (58, 59). We directly compare the
ability of currently utilized (A-L and PQ) and novel preclinical
(OZ439 andNITD609) antimalarials to reduce parasite intensity and
prevalence at multiple transmission settings. We examine these cru-
cial outputs not only within the mosquito but also following trans-
mission to subsequent vertebrate populations, demonstrating their
ability to act aspotent, single-doseTBDs.Ourdata suggest that, of the
compounds and combinations tested, PQ (at	6mg/kg) alone, or in
combinationwithA-L, andNITD609(8.1mg/kg)mayhave compar-
ativelywider utility thanotherTBIs in reducingmalaria transmission
within populations where malaria is endemic and thus merit further
consideration for field evaluation.
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